Complix is a biopharmaceutical company leading the way in the use of biologicals to target intractable or challenging disease targets.
Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access intracellular targets that are considered intractable by current drug formats. Moreover Alphabodies can effectively address therapeutic targets that are located in tissues not easily accessible by conventional antibodies, and can be delivered via non-injectable modes of administration, like oral delivery.
Conventional drug formats, such as antibodies or small chemicals, can only address a limited number of all known disease targets. Complix believes that its ability to access a much broader target space, including intracellular targets, with a high affinity protein biological will allow for the development of an entirely novel class of distinctively competitive therapeutics.
Complix is developing a transformative pipeline of Alphabody therapeutics primarily addressing intracellular disease targets that play an important role in cancer, autoimmunity and viral diseases.
The Company has multiple product candidates in its pipeline, some of which are being developed in collaboration with partners.
Cell Penetrating Alphabodies are transformative biotherapeutics created to address intracellular targets that are “undruggable” by existing therapeutics…
Complix’s drug development is initially focused on cancer and autoimmune disease, therapeutic areas that represent a significant opportunity for new therapeutic interventions based on addressing intracellular targets.